Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 1,762 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depressive Disorder, Major, Suicidal
Interventions: SLS-002, Placebo, Standard of care, Intranasal device; Drug · Other · Device
Lead sponsor: Seelos Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 21
States / cities: Orange, California • Panorama City, California • San Diego, California + 18 more

Conditions: Major Depressive Disorder, Depression
Interventions: ezogabine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Weight Gain
Interventions: Exenatide, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder, Dysthymia
Interventions: escitalopram, bupropion, imipramine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 28
States / cities: Tuscaloosa, Alabama • Little Rock, Arkansas • San Diego, California + 25 more

Conditions: Major Depressive Disorder
Interventions: Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Depression, Pain
Interventions: Duloxetine Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 25
States / cities: Peoria, Arizona • Burbank, California • Fresno, California + 22 more

Conditions: Depression
Interventions: Diazoxide, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: ADT, OPC-34712; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,036 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 32
States / cities: Arcadia, California • San Diego, California • Sherman Oaks, California + 28 more

Conditions: Major Depressive Disorder
Interventions: Olanzapine, Fluoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 30
States / cities: Oceanside, California • San Marcos, California • Torrance, California + 27 more

Conditions: Treatment Resistant Depression, Generalized Anxiety Disorder
Interventions: Genecept Assay; Device
Lead sponsor: Genomind, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 685 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chalfont, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Seltorexant, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Bryant, Arkansas • Bellflower, California • Glendale, California + 31 more

Conditions: Depressive Disorder, Major
Interventions: PCIT-ED; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 36 Months to 83 Months
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Standard Clinical Care with an SSRI; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 60 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Treatment Resistant Depression
Interventions: CERC-501, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 4
States / cities: Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more

Conditions: Major Depressive Disorder, Major Depressive Episode
Interventions: computerized cognitive remediation, computerized cognitive remediation:Control; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 89 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Depression
Interventions: Problem Solving Therapy, Dietary Education; Behavioral
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 50 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: Low Dose Fish Oil, High Dose Fish Oil; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Mental Disorders, Severe, Schizophrenia and Related Disorders, Bipolar Disorder, Depressive Disorder
Interventions: The Police-Mental Health Linkage System; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 1,405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Decatur, Georgia • Savannah, Georgia

Conditions: Major Depressive Disorder
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 46
States / cities: Bentonville, Arkansas • Bellflower, California • Garden Grove, California + 40 more

Conditions: Major Depressive Disorder, Depression, Depressive Disorder, Major
Interventions: Pramipexole, Methylphenidate, Phenelzine, Mindfulness-based Stress Sensitivity Therapy (MBSST), Complicated Grief Treatment (CGT), Care as usual (CAU) plan; Drug · Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: TBI (Traumatic Brain Injury), Depressive Disorder, Major, Clinical Depression, Mood Depressed, Physical Inactivity
Interventions: InMotion; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Major Depressive Disorder, Recurrent
Interventions: TMS positively correlated DLPFC, TMS to negatively correlated DLPFC; Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Alcoholism, Depression
Interventions: fluoxetine (Prozac), Placebo plus Treatment As Usual; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 15 Years to 20 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

Study to Treat Major Depressive Disorder (MDD) With a New Medication

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

Dichotic Listening as a Predictor of Medication Response in Depression

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic

Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and Pain

Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

A Randomized Controlled Trial of PCIT-ED for Preschool Depression

Cellular Aging and Neurobiology of Depression Study

Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression

Computerized Cognitive Remediation for Geriatric Depression

Primary Prevention of Major Depression in Later Life

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

The Police-Mental Health Linkage System

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Precision Care for Major Depressive Disorder

InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI

Investigation of Brain Network Dynamics in Depression

Pharmacological Intervention Project (Fluoxetine)